APA (7th ed.) Citation

Goldman, J. W., Mazieres, J., Barlesi, F., Dragnev, K. H., Koczywas, M., Göskel, T., . . . Paz-Ares, L. (2020). A randomized phase III study of abemaciclib versus erlotinib in patients with stage IV non-small cell lung cancer with a detectable KRAS mutation who failed prior platinum-based therapy: JUNIPER. Frontiers in oncology, 10, . https://doi.org/10.3389/fonc.2020.578756

Chicago Style (17th ed.) Citation

Goldman, Jonathan W., et al. "A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer with a Detectable KRAS Mutation Who Failed Prior Platinum-based Therapy: JUNIPER." Frontiers in Oncology 10 (2020). https://doi.org/10.3389/fonc.2020.578756.

MLA (9th ed.) Citation

Goldman, Jonathan W., et al. "A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer with a Detectable KRAS Mutation Who Failed Prior Platinum-based Therapy: JUNIPER." Frontiers in Oncology, vol. 10, 2020, https://doi.org/10.3389/fonc.2020.578756.